Prothena Corp Public (PRTA) Cash from Restructuring (2018 - 2026)
Prothena Corp Public's quarterly Cash from Restructuring came in at $480000.0 in Q1 2026, up 111.13% quarter-over-quarter from -$4.3 million in Q4 2025.
Prothena Corp Public has reported Cash from Restructuring for 4 years, with the latest figure at $480000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Restructuring changed N/A year-over-year to $480000.0; the trailing twelve-month figure through Mar 2026 stood at $13.8 million (changed N/A YoY), and the FY2025 full-year result was $13.3 million, changed N/A from the prior year.
- Cash from Restructuring for Q1 2026 stood at $480000.0, up from -$4.3 million in the prior quarter.
- The five-year high for Cash from Restructuring was $30.3 million in Q2 2025, with the low at -$12.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Prothena Corp Public | 546.75 Mn | 217.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 480,000.00 |
| Dec 31, 2025 | -4.31 Mn |
| Sep 30, 2025 | -12.72 Mn |
| Jun 30, 2025 | 30.33 Mn |
| Mar 31, 2019 | -461,000.00 |
| Dec 31, 2018 | -3.88 Mn |
| Sep 30, 2018 | -11.54 Mn |
| Jun 30, 2018 | 15.88 Mn |